Walter Ambrosius to Diabetic Retinopathy
This is a "connection" page, showing publications Walter Ambrosius has written about Diabetic Retinopathy.
Connection Strength
2.194
-
Casanova R, Saldana S, Chew EY, Danis RP, Greven CM, Ambrosius WT. Application of random forests methods to diabetic retinopathy classification analyses. PLoS One. 2014; 9(6):e98587.
Score: 0.456
-
Chew EY, Ambrosius WT. Update of the ACCORD Eye Study. N Engl J Med. 2011 Jan 13; 364(2):188-9.
Score: 0.359
-
Ambrosius WT, Danis RP, Goff DC, Greven CM, Gerstein HC, Cohen RM, Riddle MC, Miller ME, Buse JB, Bonds DE, Peterson KA, Rosenberg YD, Perdue LH, Esser BA, Seaquist LA, Felicetta JV, Chew EY. Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol. 2010 Mar; 128(3):312-8.
Score: 0.338
-
Lee D, Agron E, Keenan T, Lovato J, Ambrosius W, Chew EY. Visual acuity outcomes after cataract surgery in type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study. Br J Ophthalmol. 2022 Nov; 106(11):1496-1502.
Score: 0.185
-
Gower EW, Lovato JF, Ambrosius WT, Chew EY, Danis RP, Davis MD, Goff DC, Greven CM. Lack of Longitudinal Association Between Thiazolidinediones and Incidence and Progression of Diabetic Eye Disease: The ACCORD Eye Study. Am J Ophthalmol. 2018 03; 187:138-147.
Score: 0.145
-
Hugenschmidt CE, Lovato JF, Ambrosius WT, Bryan RN, Gerstein HC, Horowitz KR, Launer LJ, Lazar RM, Murray AM, Chew EY, Danis RP, Williamson JD, Miller ME, Ding J. The cross-sectional and longitudinal associations of diabetic retinopathy with cognitive function and brain MRI findings: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2014 Dec; 37(12):3244-52.
Score: 0.116
-
Chew EY, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C, Genuth S, Goff DC, Leiter LA, Ismail-Beigi F, Ambrosius WT. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology. 2014 Dec; 121(12):2443-51.
Score: 0.115
-
Mottl AK, Pajewski N, Fonseca V, Ismail-Beigi F, Chew E, Ambrosius WT, Greven C, Schubart U, Buse J. The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. J Diabetes Complications. 2014 Nov-Dec; 28(6):874-9.
Score: 0.114
-
Gangaputra S, Lovato JF, Hubbard L, Davis MD, Esser BA, Ambrosius WT, Chew EY, Greven C, Perdue LH, Wong WT, Condren A, Wilkinson CP, Agrón E, Adler S, Danis RP. Comparison of standardized clinical classification with fundus photograph grading for the assessment of diabetic retinopathy and diabetic macular edema severity. Retina. 2013 Jul-Aug; 33(7):1393-9.
Score: 0.107
-
Gerstein HC, Ambrosius WT, Danis R, Ismail-Beigi F, Cushman W, Calles J, Banerji M, Schubart U, Chew EY. Diabetic retinopathy, its progression, and incident cardiovascular events in the ACCORD trial. Diabetes Care. 2013 May; 36(5):1266-71.
Score: 0.103
-
Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010 Jul 15; 363(3):233-44.
Score: 0.087
-
Chew EY, Ambrosius WT, Howard LT, Greven CM, Johnson S, Danis RP, Davis MD, Genuth S, Domanski M. Rationale, design, and methods of the Action to Control Cardiovascular Risk in Diabetes Eye Study (ACCORD-EYE). Am J Cardiol. 2007 Jun 18; 99(12A):103i-111i.
Score: 0.069